Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q5VU57

UPID:
CBPC6_HUMAN

ALTERNATIVE NAMES:
ATP/GTP-binding protein-like 4; Protein deglutamylase CCP6

ALTERNATIVE UPACC:
Q5VU57; B3KT26; B4DG37

BACKGROUND:
Cytosolic carboxypeptidase 6, known for its alternative names ATP/GTP-binding protein-like 4 and Protein deglutamylase CCP6, is pivotal in mediating protein deglutamylation. It specifically targets the removal of polyglutamate side chains from tubulin and various non-tubulin proteins, including MYLK and CGAS, thereby playing a significant role in cellular structure and antiviral responses. Furthermore, CCP6's involvement in KLF4 deglutamylation underscores its importance in embryogenesis and the maintenance of cell pluripotency.

THERAPEUTIC SIGNIFICANCE:
Exploring the enzymatic functions of Cytosolic carboxypeptidase 6 offers promising avenues for therapeutic intervention. Its critical role in protein deglutamylation, antiviral defense activation, and influence on cell pluripotency maintenance highlights its potential as a target in developing novel treatments for a range of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.